[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100491097":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":22,"locations":30,"responsibleParty":131,"collaborators":7,"id":133,"slug":134,"hasResults":135,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":135,"sex":140,"minAge":7,"maxAge":7,"enrollmentInfo":141,"targetDuration":144,"studyType":145,"phases":7,"briefSummary":146,"conditions":147,"keywords":7,"overallStatus":33,"whyStopped":7,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},{"fullName":5,"class":6},"Fundación Academia Española de Dermatología","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Ciclosporin","Any systemic drug used for atopic dermatitis in clinical practice",[14,15,16,17,18,19,20,21],"Methotrexate","Dupilumab","Corticosteroids","Omalizumab","Baricitinib","Upadacitinib","Tralokimumab","Topical corticosteroids",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":7,"email":27},"Ignacio Garcia-Doval","CONTACT","34915 44 62 84","investigacion@aedv.es",{"name":29,"role":25,"phone":26,"phoneExt":7,"email":7},"Miguel Angel Descalzo Gallego",[31,47,58,68,79,90,98,109,120],{"facility":32,"status":33,"city":34,"state":35,"zip":7,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Hospital Universitari Germans Trias i Pujol","RECRUITING","Badalona","Barcelona","Spain","ES",{"type":39,"coordinates":40},"Point",[41,42],2.24741,41.45004,{"lat":42,"lon":41},[45],{"name":46,"role":25,"phone":7,"phoneExt":7,"email":7},"Jose Manuel Carrascosa, MD",{"facility":48,"status":33,"city":49,"state":7,"zip":7,"country":36,"countryCode":37,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"Hospital General Universitario de Alicante","Alicante",{"type":39,"coordinates":51},[52,53],-0.48149,38.34517,{"lat":53,"lon":52},[56],{"name":57,"role":25,"phone":7,"phoneExt":7,"email":7},"Juan Francisco Silvestre Salvador",{"facility":59,"status":33,"city":35,"state":7,"zip":7,"country":36,"countryCode":37,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Hospital del Mar IMIM",{"type":39,"coordinates":61},[62,63],2.15899,41.38879,{"lat":63,"lon":62},[66],{"name":67,"role":25,"phone":7,"phoneExt":7,"email":7},"Ana María Gimenez-Arnau",{"facility":69,"status":33,"city":70,"state":7,"zip":7,"country":36,"countryCode":37,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Hospital Universitario de Gran Canaria Dr Negrín","Las Palmas",{"type":39,"coordinates":72},[73,74],-16.16555,28.58232,{"lat":74,"lon":73},[77],{"name":78,"role":25,"phone":7,"phoneExt":7,"email":7},"Alicia González Quesada, MD",{"facility":80,"status":33,"city":81,"state":7,"zip":7,"country":36,"countryCode":37,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Hospital Infanta Leonor","Madrid",{"type":39,"coordinates":83},[84,85],-3.70256,40.4165,{"lat":85,"lon":84},[88],{"name":89,"role":25,"phone":7,"phoneExt":7,"email":7},"Pablo De la Cueva Dobao",{"facility":91,"status":33,"city":81,"state":7,"zip":7,"country":36,"countryCode":37,"cosmosGeoPoint":92,"geoPoint":94,"contacts":95},"Hospital Universitario de la Princesa",{"type":39,"coordinates":93},[84,85],{"lat":85,"lon":84},[96],{"name":97,"role":25,"phone":7,"phoneExt":7,"email":7},"Pablo Chicharro Manso",{"facility":99,"status":33,"city":100,"state":7,"zip":7,"country":36,"countryCode":37,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Complexo Hospitalario Universitario de Pontevedra","Pontevedra",{"type":39,"coordinates":102},[103,104],-8.64435,42.431,{"lat":104,"lon":103},[107],{"name":108,"role":25,"phone":7,"phoneExt":7,"email":7},"Ángeles Flórez",{"facility":110,"status":33,"city":111,"state":7,"zip":7,"country":36,"countryCode":37,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Hospital Universitario y Politécnico la Fe","Valencia",{"type":39,"coordinates":113},[114,115],-0.37966,39.47391,{"lat":115,"lon":114},[118],{"name":119,"role":25,"phone":7,"phoneExt":7,"email":7},"Mercedes Rodríguez Älvarez",{"facility":121,"status":33,"city":122,"state":7,"zip":7,"country":36,"countryCode":37,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Hospital Miguel Servet","Zaragoza",{"type":39,"coordinates":124},[125,126],-0.87734,41.65606,{"lat":126,"lon":125},[129],{"name":130,"role":25,"phone":7,"phoneExt":7,"email":7},"Yolanda Gilaberte",{"type":132,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100491097","spanish-academy-of-dermatology-and-venereology-registry-of-atopic-dermatitis-therapy-100491097",false,"NCT05674695","Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy","BIOBADATOP","Inclusion Criteria:\n\n1. Paediatric and adult patients with atopic eczema who due to the severity of their disease and\u002For impact on quality of life are commencing on or switching to a specific systemic immuno-modulatory agent (e.g. CyA, AZA, MTX or new\u002Fbiologic treatments) for the first time in their life (might have received others, but not this specific one).\n2. Diagnosis of atopic eczema in keeping with the UK\u002FIrish diagnostic criteria.\n3. Willingness to comply with all study requirements.\n\nExclusion Criteria:\n\n1. Insufficient understanding of the study by the patient and\u002For parent\u002Fguardian.\n2. Patients who are currently participating in a randomised clinical trial.\n3. Intention to move to a different geographical area in a short-term (next 3 months).","ALL",{"count":142,"type":143},2500,"ESTIMATED","5 Years","OBSERVATIONAL","The Spanish Registry of Systemic therapy in atopic eczema, BIOBADATOP, assesses drug safety and treatment effectiveness as well as treatment impact on quality of life in children and adults with atopic eczema receiving systemic immuno-modulatory therapies in Spanish daily practice.\n\nThe main objectives are:\n\n1. To assess short and long-term safety of systemic therapies (including phototherapy) for atopic eczema (pharmacovigilance).\n2. To assess short and long-term effectiveness of systemic therapies, providing a basis for shared decision making and guidelines.\n\nSecondary objectives are:\n\n1. To assess short and long-term safety of topical therapies for atopic eczema.\n2. To assess effectiveness of different methods of care, including patient training.\n3. To describe atopic dermatitis comorbidities.",[148],"Dermatitis, Atopic","2023-01-05",{"date":151,"type":152},"2023-01-06","ACTUAL",{"date":154,"type":152},"2019-01-01",{"date":156,"type":143},"2029-01-01",{"name":5,"class":6},9]